Patents by Inventor Stephen C. Yabut

Stephen C. Yabut has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist
    Patent number: 8673890
    Abstract: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.
    Type: Grant
    Filed: October 28, 2010
    Date of Patent: March 18, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: Han-Cheng Zhang, Bruce Maryanoff, Kimberly White, Stephen C. Yabut, Hong Ye, Cailin Chen
  • Spiropiperidines for use as tryptase inhibitors
    Patent number: 8536189
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 17, 2013
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • SPIROPIPERIDINES FOR USE AS TRYPTASE INHIBITORS
    Publication number: 20120165327
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Application
    Filed: March 1, 2012
    Publication date: June 28, 2012
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • Spiropiperidines for use as tryptase inhibitors
    Patent number: 8158792
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Grant
    Filed: November 19, 2008
    Date of Patent: April 17, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST
    Publication number: 20110105490
    Abstract: The present invention is directed to novel 2,3-dihydro-1H-isoindol-1-imine derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the thrombin PAR-1 receptor antagonists.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 5, 2011
    Inventors: Han-Cheng Zhang, Bruce Maryanoff, Kimberly White, Stephen C. Yabut, Hong Ye, Cailin Chen
  • Substituted spiroheterocycles
    Patent number: 7825111
    Abstract: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: November 2, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Min A. Xiang, Mona Patel, Philip Rybczynski, Joseph Gunnet, Keith T. Demarest, Richard Look, Bruce Maryanoff, Michael J. Costanzo, Stephen C. Yabut
  • Substituted spiroheterocycles
    Patent number: 7825110
    Abstract: The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I, which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: November 2, 2010
    Assignee: Janssen Pharmaceutica NV
    Inventors: Min A. Xiang, Mona Patel, Philip Rybczynski, Joseph Gunnet, Keith T. Demarest, Richard Look, Bruce Maryanoff, Michael J. Costanzo, Stephen C. Yabut
  • Spiropiperidines for use as tryptase inhibitors
    Publication number: 20090163527
    Abstract: The present invention is directed to a compound of Formula (I): or a form thereof, wherein X1, X2, X3, X4, R1, R2 and R3 are as defined herein, useful as tryptase inhibitors.
    Type: Application
    Filed: November 19, 2008
    Publication date: June 25, 2009
    Inventors: Michael J. Costanzo, Stephen C. Yabut, Brett Tounge, Bruce E. Maryanoff, Han-Cheng Zhang
  • SPIROBENZOAZEPANES AS VASOPRESSIN ANTAGONISTS
    Publication number: 20080306044
    Abstract: The present invention is directed to a compound of Formula (I) or a form thereof: wherein U, V, W and Ring A are as defined herein, useful as vasopressin receptor antagonists.
    Type: Application
    Filed: June 6, 2008
    Publication date: December 11, 2008
    Inventors: MICHAEL J. COSTANZO, David F. McComsey, Stephen C. Yabut, Han-Cheng Zhang
  • Peptidyl heterocyclic ketones useful as tryptase inhibitors
    Patent number: 7132418
    Abstract: The present invention relates to a series of peptidyl heterocyclic ketones which are inflammatory cell serine protease inhibitors and their compositions and methods for the prevention and treatment of a variety of immunomediated inflammatory disorders. More particularly, these compounds are potent and selective inhibitors of tryptase and are therefore effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: November 7, 2006
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Michael J. Costanzo, Bruce E. Maryanoef, Stephen C. Yabut
  • Peptidyl heterocyclic ketones useful as tryptase inhibitors
    Publication number: 20030008829
    Abstract: The present invention relates to a series of peptidyl heterocyclic ketones which are inflammatory cell serine protease inhibitors and their compositions and methods for the prevention and treatment of a variety of immunomediated inflammatory disorders. More particularly, these compounds are potent and selective inhibitors of tryptase and are therefore effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis.
    Type: Application
    Filed: July 25, 2002
    Publication date: January 9, 2003
    Inventors: Michael J. Costanzo, Bruce E. Maryanoef, Stephen C. Yabut
  • Peptidyl heterocyclic ketones useful as tryptase inhibitors
    Patent number: 6469036
    Abstract: The present invention relates to a series of peptidyl heterocyclic ketones which are inflammatory cell serine protease inhibitors and their compositions and methods for the prevention and treatment of a variety of immunomediated inflammatory disorders. More particularly, these compounds are potent and selective inhibitors of tryptase and are therefore effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: October 22, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Michael J. Costanzo, Bruce E. Maryanoff, Stephen C. Yabut